- Home
- BRT vs CERS Comparison
BRT vs CERS Comparison
Compare BRT & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRT
- CERS
- Stock Information
- Founded
- BRT 1972
- CERS 1991
- Country
- BRT United States
- CERS United States
- Employees
- BRT N/A
- CERS N/A
- Industry
- BRT Real Estate Investment Trusts
- CERS EDP Services
- Sector
- BRT Real Estate
- CERS Technology
- Exchange
- BRT Nasdaq
- CERS Nasdaq
- Market Cap
- BRT 331.7M
- CERS 347.3M
- IPO Year
- BRT N/A
- CERS 1997
- Fundamental
- Price
- BRT $16.53
- CERS $1.38
- Analyst Decision
- BRT Strong Buy
- CERS Strong Buy
- Analyst Count
- BRT 3
- CERS 2
- Target Price
- BRT $21.83
- CERS $3.50
- AVG Volume (30 Days)
- BRT 31.5K
- CERS 1.5M
- Earning Date
- BRT 03-12-2025
- CERS 05-01-2025
- Dividend Yield
- BRT 6.07%
- CERS N/A
- EPS Growth
- BRT N/A
- CERS N/A
- EPS
- BRT N/A
- CERS N/A
- Revenue
- BRT $97,274,000.00
- CERS $180,270,000.00
- Revenue This Year
- BRT $5.43
- CERS $25.22
- Revenue Next Year
- BRT $5.39
- CERS $10.08
- P/E Ratio
- BRT N/A
- CERS N/A
- Revenue Growth
- BRT 1.65
- CERS 15.29
- 52 Week Low
- BRT $15.92
- CERS $1.34
- 52 Week High
- BRT $20.22
- CERS $2.54
- Technical
- Relative Strength Index (RSI)
- BRT 32.46
- CERS 35.86
- Support Level
- BRT $17.75
- CERS $1.40
- Resistance Level
- BRT $18.37
- CERS $1.58
- Average True Range (ATR)
- BRT 0.59
- CERS 0.08
- MACD
- BRT -0.16
- CERS -0.00
- Stochastic Oscillator
- BRT 5.33
- CERS 16.00
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is primarily focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.